Investors are always looking for stocks that are poised to beat at earnings season and Ascendis Pharma A/S (ASND) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Ascendis Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a prett ...

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and webcast on February 7, 2024, at 4:30 p.m. Eastern Time (ET) to discuss 2023 financial results. Those who would like to participate may access the live webcast here, or register in advance for the ...

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria. YORVIPATH is the second product developed with Ascendis Pharma's TransCon technology platform to be launched commercially. "We are pleased to initiate the launch of YORVIPATH to add ...

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology product ...

BUCHAREST, Romania, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced it has entered into an exclusive distribution agreement with Danish Company Ascendis Pharma A/S (NASDAQ:ASND) for its endocrinology portfolio. Under the agreement, Er-Kim is appointed as the exclusive Ascendis A/S endocrinology distributor in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Estonia, Greece, Hungary ...

DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (NASDAQ:ASND) to commercialize both Skytrofa™ and Yorvipath™ in the Gulf Cooperation Council (GCC) countries of Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain. Under the terms of this exclusive distribution agreement, Vector will employ its sales and marketing expertise to distribut ...

Strategic roadmap to achieve blockbuster status for multiple products and expand the Company's engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference. "With unwavering focus on our values of Patients, Sci ...

Core Points - Specialised Therapeutics Asia Pte Ltd (ST) has entered into an exclusive distribution agreement with Ascendis Pharma A/S for three endocrinology therapies, expanding its portfolio in the region [1][2] - The agreement covers key markets including Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam [1][2] - Two of the therapies, SKYTROFA and YORVIPATH, are already approved internationally, while the third, TransCon CNP, is in development following successful Phase 2 trial results [1][2][3] Product Details - SKYTROFA (lonapegsomatropin) is a once-weekly injectable human growth hormone treatment approved in the US and EU for pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone [2][8] - YORVIPATH (palopegteriparatide) is a first-in-class parathyroid hormone replacement therapy approved in the EU for adults with chronic hypoparathyroidism, addressing a significant unmet medical need [2][3][12] - TransCon CNP (navepegritide) is an investigational therapy for achondroplasia, showing promising results in Phase 2 trials for improving growth velocity in children [1][2][14] Strategic Importance - The partnership marks a significant milestone for ST, indicating its expansion into endocrinology and pediatric medicine [3][4] - ST's CEO emphasized the importance of this agreement in launching critical endocrinology products in the targeted regions [3][4] - Ascendis Pharma's selection of ST as a partner is based on ST's strong track record in commercializing specialist medicines across multiple regions [4][5] Market Context - The agreement aligns with ST's mission to provide specialty therapies where there is an unmet need, enhancing its therapeutic pipeline [6][4] - ST has established itself as the largest independent specialty pharmaceutical company in the region, navigating complex regulatory and commercialization environments [6]

Financial Data and Key Metrics Changes - Total revenue for Q3 2023 was €48 million, with SKYTROFA revenue at €47 million, up from €35.9 million in Q2 2023 and €12.3 million in Q3 2022 [20][21] - Operating loss decreased sequentially by 5% to €134 million from €141 million in Q2 2023 [21] - Cash, cash equivalents, and marketable securities totaled €455 million at the end of Q3 2023 [22] Business Line Data and Key Metrics Changes - SKYTROFA revenue growth was primarily driven by increased demand in the U.S., with low double-digit penetration into the U.S. pediatric growth hormone deficiency patient population [20][21] - R&D costs in Q3 totaled €111.4 million, up 6% sequentially, driven by higher endocrine rare disease-related costs [21] - SG&A expenses declined 9% sequentially, reflecting lower commercial and G&A external costs [21] Market Data and Key Metrics Changes - The company expects full-year 2023 SKYTROFA revenue to be between €170 million and €175 million, reflecting strong market demand [9][22] - The addressable U.S. growth hormone market is estimated to be significantly larger than current penetration levels, indicating growth opportunities [21] Company Strategy and Development Direction - The company aims to become a leading global pharma company focused on endocrinology rare diseases, with plans to launch three independent products by 2025 [8][19] - The strategy includes direct sales models in select European countries and partnerships in other markets [7][8] - Future growth will leverage fully integrated capabilities and partnerships in oncology and ophthalmology [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability and highlighted the importance of addressing co-morbidities associated with diseases treated by their products [18][30] - The company is preparing for its next vision for growth to 2030, focusing on sustainable value creation for patients and shareholders [18][19] Other Important Information - TransCon PTH is expected to launch in Germany in January 2024, pending European Commission approval [10][11] - The company is exploring combination therapies to enhance treatment outcomes for achondroplasia [15][41] Q&A Session Summary Question: Strategy with oncology and ophthalmology programs - The company will focus on rare disease endocrinology while exploring out-licensing and partnerships in other therapeutic areas [25][27] Question: Update from the Phase II accomplish trial - The company aims to provide data on sustainability of treatment benefits beyond height velocity [29][30] Question: TransCon PTH positioning in Europe - The company expects a strong market position in Germany due to high patient demand and reimbursement support [31][32] Question: Competing hGH products in the U.S. - Management noted strong interest and market performance for SKYTROFA despite competition [35][36] Question: TransCon CNP benefits beyond height velocity - The company is investigating various endpoints, including patient-reported outcomes and co-morbidities [52][53] Question: Plans for TransCon IL-2 expansion - The company is encouraged by initial data and is exploring additional indication cohorts in lung cancer [50][51]

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President and Chief Financial Officer Conference Call Participants Li Watsek - Cantor Paul Choi - Goldman Sachs Andreas Argyrides - Wedbush Securities David Lebovitz - Citi Leland Gershell - Oppenheimer Operator Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Confer ...